Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy of Ustekinumab in Patients With Palmo-Plantar Pustular Psoriasis or With Palmo-Plantar Pustulosis

This study has been terminated.
(Manufacturer ceased to produce vials used for this study.)
Sponsor:
Collaborator:
Janssen-Ortho LLC
Information provided by (Responsible Party):
Innovaderm Research Inc.
ClinicalTrials.gov Identifier:
NCT01091051
First received: March 18, 2010
Last updated: June 10, 2013
Last verified: June 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2011
  Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)